Seegene, Inc. (KOSDAQ:096530)
26,550
+250 (0.95%)
May 2, 2025, 3:30 PM KST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Molecular Diagnostics and Reagent Goods | 288.03B |
Log In |
Log In |
Log In |
Log In |
Molecular Diagnostics and Reagent Goods Growth | -58.31% |
Log In |
Log In |
Log In |
Log In |
Molecular Diagnostics and Reagent Merchandise | 65.72B |
Log In |
Log In |
Log In |
Log In |
Molecular Diagnostics and Reagent Merchandise Growth | -56.88% |
Log In |
Log In |
Log In |
Log In |
Other | 13.62B |
Log In |
Log In |
Log In |
Log In |
Other Growth | 31.97% |
Log In |
Log In |
Log In |
Log In |
Other | 13.62B |
Log In |
Log In |
Log In |
Log In |
Other Growth | 31.97% |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Other | 12.42B |
Log In |
Log In |
Log In |
Log In |
Other Growth | -38.84% |
Log In |
Log In |
Log In |
Log In |
Reconciling Items | - |
Log In |
Log In |
Log In |
Log In |
Reconciling Items Growth | - |
Log In |
Log In |
Log In |
Log In |
South Korea | 198.56B |
Log In |
Log In |
Log In |
Log In |
South Korea Growth | -57.47% |
Log In |
Log In |
Log In |
Log In |
Europe | 109.99B |
Log In |
Log In |
Log In |
Log In |
Europe Growth | -53.87% |
Log In |
Log In |
Log In |
Log In |
Americas | 46.40B |
Log In |
Log In |
Log In |
Log In |
Americas Growth | -63.75% |
Log In |
Log In |
Log In |
Log In |
Other | 12.42B |
Log In |
Log In |
Log In |
Log In |
Other Growth | -38.84% |
Log In |
Log In |
Log In |
Log In |
Reconciling Items | - |
Log In |
Log In |
Log In |
Log In |
Reconciling Items Growth | - |
Log In |
Log In |
Log In |
Log In |